On June 1, 2026, the Centers for Medicare and Medicaid Services issued an interim final rule (IFR) with comment period to implement provisions in Public Law 119-21 (also known as “H.R. 1” or the "One Big Beautiful Bill Act").
Press release announcing that The Main Street Pharmacy Access Act has advanced in the Ways and Means Committee. AMCP thanks committee members for their leadership and recognizes the role AMCP members played in advocating directly with lawmakers to help move this issue forward. This legislation is an important step toward improving access to pharmacist-provided care for Medicare patients — in states that already authorize pharmacists to perform these services.
In this video, Shelby Cole shares her experience living with narcolepsy type one with cataplexy, a chronic neurological disorder that affects the body’s ability to regulate sleep and wake cycles.
A roundup of Prime's award-winning presentations and insights at AMCP 2026 in Nashville, Tennessee
On April 21, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a Status Update on the Medicare GLP-1 BRIDGE Demo and BALANCE Model in Part D for CY 2027.
The AMCP Research Institute (ARI) announced the launch of Cardiometabolic Health Real-world Outcomes & Management Evaluation (CHROME), a multisite research initiative designed to evaluate the effectiveness, structure, and economic impact of comprehensive cardiometabolic care models such as Cardiometabolic Centers of Excellence (CoEs) and dedicated obesity clinics. This collaborative research initiative is supported by Lilly and will generate real-world evidence intended to help inform best-practice recommendations and implementation guidance to support scalable cardiometabolic care nationwide.
